MALVERN, Pa., March 23 /PRNewswire/ -- Fujirebio Diagnostics, Inc., the premier cancer diagnostics company and the industry leader in cancer biomarker assays, today announced the appointment of Grady Barnes, Ph.D. as Chief Scientific Officer. Dr. Barnes comes to Fujirebio Diagnostics with 25 years of diagnostics experience. He has held various positions at Abbott and Meridian Bioscience, most recently as Vice President of Research & Development at Meridian Bioscience.
As Chief Scientific Officer, Dr. Barnes will be responsible for all scientific affairs including research and development, product development, process engineering and clinical and regulatory affairs. He will also assist in the selection of new product candidates and licensing opportunities for Fujirebio Diagnostics products.
"Dr. Barnes' extensive experience in diagnostics will be vital to sustaining Fujirebio Diagnostics' growth," says Paul Touhey, President and CEO of Fujirebio Diagnostics. "His expertise will support the growth and acceptance of biomarker assays in ovarian cancer, such as HE4, and help Fujirebio Diagnostics identify additional promising biomarkers in oncology."
Barnes received a Bachelor of Arts degree in natural sciences from
About Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is one of the group companies of Miraca Holdings, Inc., in Japan, s
|SOURCE JFK Communications, Inc.|
Copyright©2009 PR Newswire.
All rights reserved